Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oligometastatic Disease Clear all
Completed No phase listed Observational

Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

NCT02170181
View directory record Official record
Conditions
Cancer Patients Receiving Stereotactic Body RTX
Interventions
SBRT
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 23, 2026, 11:42 PM EDT
Suspended Phase 2 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

NCT03575611
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Terminated Phase 2 Interventional Results available

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

NCT05846646
View directory record Official record
Conditions
Oligometastatic Disease
Interventions
IMSA101, Immune checkpoint inhibitor, PULSAR
Drug · Radiation
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Irvine, California • Kansas City, Kansas • New Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

NCT04011410
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
Hydroxychloroquine Sulfate 200Mg Tab
Drug
Lead sponsor
Patrick Hensley
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 23, 2026, 11:42 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NCT03808662
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions
Sterotactic Body Radiotherapy/SBRT, Standard of care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation for Prostate Oligometastases

NCT02680587
View directory record Official record
Conditions
Prostate Cancer, Oligometastases
Interventions
SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer

NCT02716974
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Bicalutamide, Docetaxel, Prostatectomy, Radiation
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

NCT01725165
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery
Other · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Interventions
Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
San Carlos, California • Hartford, Connecticut • Norwalk, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting No phase listed Observational

Registry for Esophageal and Gastroesophageal Junction Cancer

NCT06558786
View directory record Official record
Conditions
Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions
EORTC QLQ-C30 questionnaire, QLQ-OGS25 questionnaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Not applicable Interventional

Radiosurgery for Patients Recurrent Oligometastatic Disease

NCT01345552
View directory record Official record
Conditions
Recurrent Oligometastatic Disease
Interventions
Stereotactic Radiosurgery (SRS)
Radiation
Lead sponsor
Steven Burton
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jul 23, 2026, 11:42 PM EDT
Terminated Phase 2 Interventional Results available

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

NCT04975516
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
Interventions
Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

NCT03503344
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Apalutamide, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

NCT03707184
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Drug
Lead sponsor
University of Utah
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 23, 2026, 11:42 PM EDT
Not listed Phase 2 Interventional

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962
View directory record Official record
Conditions
Stage IV or Recurrent Carcinoma or Sarcoma
Interventions
Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose, Subtotal surgical removal plus ablative radiation dose, Radioembolization
Procedure · Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Boulder, Colorado • Littleton, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

NCT03358563
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 23, 2026, 11:42 PM EDT
Completed Early Phase 1 Interventional

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT01781741
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment
Combination Product · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 11:42 PM EDT
Active, not recruiting Phase 3 Interventional

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

NCT05863351
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Ablative Radiotherapy, Systemic Therapy
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
108
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Not yet recruiting Not applicable Interventional

Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing

NCT06842030
View directory record Official record
Conditions
Personalized Medicine, Oligometastatic Disease, Feasibility
Interventions
Darwin OncoTarget and OncoTreat
Diagnostic Test
Lead sponsor
Good Samaritan Hospital Medical Center, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Islip, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Early Phase 1 Interventional

Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography

NCT06373497
View directory record Official record
Conditions
Oligometastatic Disease
Interventions
18-F-NaF Cardiac PET/MRI and, CT Angiogram
Diagnostic Test
Lead sponsor
Katelyn Atkins
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Not applicable Interventional

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

NCT06796543
View directory record Official record
Conditions
Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Consolidative radiation therapy (cRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 39 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

NCT05501665
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab
Procedure · Drug · Other + 2 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

NCT05534438
View directory record Official record
Conditions
Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 11:42 PM EDT
Recruiting Phase 3 Interventional

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414
View directory record Official record
Conditions
Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
41
States / cities
Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 11:42 PM EDT